Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.45 |
| ▸ | PPARD | Q03181 | 5/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 2/20 | 0.42 |
| ▸ | PPARA | Q07869 | 2/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.42 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.40 |
| ▸ | LTB4R | Q15722 | 2/20 | 0.40 |
| ▸ | GCGR | P47871 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4421579 | 0.88 | PPARG (0.44) | FFAR4PPARDPPARGPPARA | |
| SCHEMBL4420148 | 0.81 | FFAR4 (0.56) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL4427558 | 0.78 | FFAR4 (0.49) | FFAR4FFAR1PPARDS1PR1PPARG | |
| SCHEMBL1549699 | 0.78 | PPARD (0.66) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL4424891 | 0.76 | PPARG (0.50) | FFAR4FFAR1PPARDPPARGPPARA | |
| SCHEMBL4420617 | 0.71 | PPARG (0.45) | FFAR4PPARDS1PR1PPARGPPARA | |
| SCHEMBL16048767 | 0.69 | FFAR4 (0.78) | FFAR4 | |
| SCHEMBL2533427 | 0.67 | FFAR4 (0.51) | FFAR4FFAR1PPARDS1PR1PPARA | |
| SCHEMBL2539389 | 0.67 | FFAR4 (0.51) | FFAR4FFAR1PPARDS1PR1PPARA | |
| SCHEMBL1549560 | 0.67 | PPARD (0.54) | FFAR4FFAR1PPARDPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7495001-B2 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | claimed |
| JP-2007509998-A | — | — | 2007-04-19 | — | — | JP | claimed |
| EP-1682507-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | claimed |
| WO-2005049572-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | claimed |
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | claimed |
| US-7495001-B2 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2009-02-24 | — | — | US | disclosed |
| EP-1682507-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| WO-2005049572-A1 | BENZANNELATED COMPOUNDS AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096336-A1 | Benzannelated derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | FFAR4 5/4885FFAR1 10/4885PPARD 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.